Antiproliferative effect of deferiprone on the Hep G2 cell line

被引:33
作者
Chenoufi, N [1 ]
Drénou, B
Loréal, O
Pigeon, C
Brissot, P
Lescoat, G
机构
[1] Pontchaillou Univ Hosp, INSERM, Liver Res Unit, U49, F-35033 Rennes, France
[2] Pontchaillou Univ Hosp, Hematol Lab, F-35033 Rennes, France
[3] Pontchaillou Univ Hosp, Liver Dis Unit, F-35033 Rennes, France
关键词
deferoxamine; deferiprone; iron; DNA synthesis; cell cycle; HepG2 cell line;
D O I
10.1016/S0006-2952(98)00071-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Iron is an essential element in cellular metabolism and the growth of all living species, and is involved in DNA replication. The risk of hepatocellular carcinoma development is associated with an increase in iron availability. The aim of the present work was to investigate the effect of an oral iron chelator, deferiprone (CP20), on HepG2 cell-line proliferation in culture. HepG2 cell cultures were maintained in the absence of fetal calf serum (FCS) and in the presence or not (control cultures) of CP20 at the concentrations of 50 or 100 ELM; deferoxamine (DFO) was used as an iron chelator reference. Cell proliferation was investigated by the analysis of DNA synthesis using [H-3] methyl-thymidine incorporation and of the cell cycle by flow cytometry. Iron chelation efficiency in the culture model was studied by analyzing the effect of CP20 on radioactive iron uptake, intracellular ferritin level, and transferrin receptor expression. CP20, at the concentration of 50 or 100 mu M, inhibited DNA synthesis after 48 hr of incubation and induced an accumulation of the cells in the S phase of the cell cycle. Iron chelators inhibited cellular iron uptake, decreased intracellular ferritin level, and increased transferrin receptor protein and mRNA levels. Our results show that CP20 as well as deferoxamine inhibit HepG2 cell proliferation and block cell cycle in the S phase. BIOCHEM PHARMACOL 56;4:431-437, 1998. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:431 / 437
页数:7
相关论文
共 37 条
[1]   LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL [J].
AGARWAL, MB ;
GUPTE, SS ;
VISWANATHAN, C ;
VASANDANI, D ;
RAMANATHAN, J ;
DESAI, N ;
PUNIYANI, RR ;
CHHABLANI, AT .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (02) :460-466
[2]   INCREASED RISK OF HEPATOCELLULAR-CARCINOMA DEVELOPMENT IN PATIENTS WITH CIRRHOSIS AND WITH HIGH HEPATOCELLULAR PROLIFERATION [J].
BALLARDINI, G ;
GROFF, P ;
ZOLI, M ;
BIANCHI, G ;
GIOSTRA, F ;
FRANCESCONI, R ;
LENZI, M ;
ZAULI, D ;
CASSANI, F ;
BIANCHI, F .
JOURNAL OF HEPATOLOGY, 1994, 20 (02) :218-222
[3]  
BECTON DL, 1989, CANCER RES, V49, P4809
[4]   THE EFFECT OF DESFERRIOXAMINE ON TRANSFERRIN RECEPTORS, THE CELL-CYCLE AND GROWTH-RATES OF HUMAN-LEUKEMIC CELLS [J].
BOMFORD, A ;
ISAAC, J ;
ROBERTS, S ;
EDWARDS, A ;
YOUNG, S ;
WILLIAMS, R .
BIOCHEMICAL JOURNAL, 1986, 236 (01) :243-249
[5]  
BRODIE C, 1993, CANCER RES, V53, P3968
[6]   Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate [J].
Chenoufi, N ;
Loreal, O ;
Drenou, B ;
Cariou, S ;
Hubert, N ;
Leroyer, P ;
Brissot, P ;
Lescoat, G .
JOURNAL OF HEPATOLOGY, 1997, 26 (03) :650-658
[7]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[8]   PRENEOPLASTIC SIGNIFICANCE OF HEPATIC IRON-FREE FOCI IN GENETIC HEMOCHROMATOSIS - A STUDY OF 185 PATIENTS [J].
DEUGNIER, YM ;
CHARALAMBOUS, P ;
LEQUILLEUC, D ;
TURLIN, B ;
SEARLE, J ;
BRISSOT, P ;
POWELL, LW ;
HALLIDAY, JW .
HEPATOLOGY, 1993, 18 (06) :1363-1369
[9]  
DONFRANCESCO A, 1990, CANCER RES, V50, P4929
[10]   DEFEROXAMINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN, AND THIOTEPA (D-CECAT) - A NEW CYTOREDUCTIVE CHELATION-CHEMOTHERAPY REGIMEN IN PATIENTS WITH ADVANCED NEUROBLASTOMA [J].
DONFRANCESCO, A ;
DEB, G ;
DOMINICI, C ;
ANGIONI, A ;
CANIGLIA, M ;
DESIO, L ;
FIDANI, P ;
AMICI, A ;
HELSON, L .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (04) :319-322